SCHEMBL2022440

SCHEMBL2022440

COCCS(=O)(=O)c1ccc(/C(=C\C2CC(F)C(F)C2)C(=O)Nc2nccs2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 6/20 0.55
ALDH1A1 P00352 5/20 0.42
LMNA P02545 4/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
TSHR P16473 3/20 0.41
USP2 O75604 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
HSD17B10 Q99714 2/20 0.41
STAT3 P40763 1/20 0.41
POLB P06746 3/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
KCNH2 Q12809 1/20 0.39
MAPK1 P28482 2/20 0.38
GBA1 P04062 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2024574 1.00 GCK (0.55) GCKALDH1A1LMNAGAAMEN1
SCHEMBL2028193 0.89 GCK (0.60) GCKALDH1A1LMNAGAAMEN1
SCHEMBL2028191 0.89 GCK (0.60) GCKALDH1A1LMNAGAAMEN1
SCHEMBL2044077 0.85 GCK (0.74) GCKALDH1A1TSHRPOLB
SCHEMBL2019857 0.85 GCK (0.74) GCKALDH1A1TSHRPOLB
SCHEMBL2051355 0.85 GCK (0.74) GCKALDH1A1TSHRPOLB
SCHEMBL2049111 0.85 GCK (0.74) GCKALDH1A1TSHRPOLB
SCHEMBL2019859 0.85 GCK (0.74) GCKALDH1A1TSHRPOLB
SCHEMBL2018854 0.82 GCK (0.38) GCKKCNH2
SCHEMBL2018852 0.82 GCK (0.38) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275414-B1 CYCLOPENTYLACRYLAMIDE DERIVATIVE KYORIN SEIYAKU KK (JP) 2015-06-10 EP claimed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US claimed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 GCK 188/4885ALDH1A1 606/4885LMNA 2676/4885
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 GCK 188/4885ALDH1A1 606/4885LMNA 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.